Focal Adhesion Kinase (FAK) tyrosine 397E mutation restores the vascular leakage defect in endothelium‐specific FAK‐kinase dead mice

Focal adhesion kinase (FAK) inhibitors have been developed as potential anticancer agents and are undergoing clinical trials. In vitro activation of the FAK kinase domain triggers autophosphorylation of Y397, Src activation, and subsequent phosphorylation of other FAK tyrosine residues. However, how...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Pathol
Autori principali: Alexopoulou, Annika N, Lees, Delphine M, Bodrug, Natalia, Lechertier, Tanguy, Fernandez, Isabelle, D'Amico, Gabriela, Dukinfield, Matthew, Batista, Silvia, Tavora, Bernardo, Serrels, Bryan, Hodivala‐Dilke, Kairbaan
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley & Sons, Ltd 2017
Soggetti:
Original Papers
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5518444/
https://ncbi.nlm.nih.gov/pubmed/28444899
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/path.4911
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi